Study of GV20-0251 in Participants With Solid Tumor Malignancies

Exclusion Criteria

• •Participants with acute leukemia or CLL
• •Participant with heart disease (NYHA ≥ Level II), myocardial infarction within the past 6 months, or unstable arrhythmia
• •Fridericia-corrected QT interval (QTcF) \> 470 msec, or the presence of congenital long QT syndrome, or a history of clinically significant electrocardiogram (ECG) abnormalities (including pericarditis) that, in the investigator's judgment, may affect the subject's safety.
• •Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy within 7 days before C1D1
• •Participant has active autoimmune disease or other medical conditions requiring chronic systemic steroid or immunosuppressive therapy
• •Known human immunodeficiency virus (HIV) infection, known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection, unless meeting the specific conditions.
• •History of major organ transplant and/or a bone marrow transplant
• •Symptomatic central nervous system (CNS) malignancy or metastasis
• •Serious nonmalignant disease
• •Pregnant or nursing women
• •Major surgery within 28 days prior to the first dose of study medication
• •Prior anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GV20-0251 on Cycle 1 Day 1 (C1D1), with the exceptions.
• •History of severe allergic reactions to biologic therapy, which in the investigator's judgment may increase the subject's risk.
• •Radiation therapy for symptomatic lesions within 14 days prior to C1D1 dosing.
• •Active substance abuse
• •Any history of an immune-related ≥ Grade 3 AE attributed to prior cancer immunotherapy